Back to search

National and Kapodistrian University of Athens

The interplay of DNA damage response and immune system network in lung cancer therapy

Abstract

dc:description

Lung cancer remains one of the most prevalent malignancies globally, characterized by persistently high mortality rates. Its pathogenesis has been strongly linked to exposure to DNA-damaging agents, resulting in genomic instability and elevated mutational burden. Standard-of-care treatment typically involves platinum-based chemotherapy and immunotherapy, particularly immune checkpoint inhibitors (ICIs). Central to the cellular response to genotoxic stress is the DNA damage response (DDR) network, a complex system responsible for detecting and repairing DNA lesions or initiating apoptosis. Disruption of DDR mechanisms contributes to genomic instability, driving tumorigenesis, and also exerts profound effects on immune regulation—features that underscore its therapeutic relevance. Moreover, intracellular redox homeostasis, often assessed via the reduced/oxidized glutathione ratio (GSH/GSSG), is critical for maintaining cell viability and modulating signaling cascades, and is closely linked to the formation of DNA damage. This study aimed to investigate the interplay between DDR and the immune system in the context of the anti-tumor response in lung cancer. DDR-related parameters and redox status were assessed in two lung cancer cell lines (A549, H1299), two normal fibroblast lines (WS1, 1BR3hT), and peripheral blood mononuclear cells (PBMCs) from 20 healthy donors and 32 lung cancer patients at baseline—comprising 17 responders and 15 non-responders to subsequent platinum-based chemotherapy. Compared to normal fibroblasts, lung cancer cell lines exhibited significantly higher baseline DNA damage, increased apurinic/apyrimidinic (AP) site formation, decreased GSH/GSSG ratios, impaired nucleotide excision repair (NER), and enhanced interstrand cross-link (ICL) repair efficiency (all p < 0.05). Similarly, PBMCs from patients with lung cancer demonstrated reduced redox capacity, increased DNA damage, diminished DNA repair functionality, and attenuated apoptotic responses relative to healthy controls (all p < 0.001). Notably, responder patients displayed higher AP site burden, lower GSH/GSSG ratios, reduced NER and ICL repair capacity, and increased apoptosis compared to non-responders (all p < 0.01). These findings suggest that DDR and redox parameters may serve as non-invasive biomarkers to predict therapeutic responsiveness to platinum-based regimens.Among the key regulators of DDR are the kinases ATR (ataxia telangiectasia and Rad3-related) and ATM (ataxia-telangiectasia mutated). Emerging evidence indicates that ATR inhibition induces synthetic lethality in ATM-deficient tumors and may potentiate anti-tumor immunity by enhancing tumor mutational burden and neoantigen presentation. Additionally, ATR inhibition promotes cytosolic DNA accumulation, activating the cGAS–STING pathway and type I interferon signaling. Thus, targeting ATR represents a promising therapeutic approach, either as monotherapy or in combination with genotoxic agents and/or immunomodulatory therapies.We evaluated the efficacy of the ATR inhibitor AZD6738 both in vitro and in vivo. In lung cancer cell lines (A549, H1299) and the murine line LLC, combination treatment with AZD6738 and cisplatin significantly increased DNA damage, AP site formation, and oxidative stress. H1299 cells (p53-deficient) were particularly sensitive to ATR inhibition followed by UV-C irradiation, demonstrating pronounced genomic stress and redox imbalance. These results underscore the potential of ATR inhibition as a therapeutic strategy, contingent on tumor genotype and optimized dosing regimens. Specifically, tumors harboring ATM mutations may derive greater benefit from ATR-targeted therapies in combination with chemotherapy or immunotherapy.To explore this approach in vivo, a syngeneic heterotopic lung cancer model was established via subcutaneous implantation of LLC cells into C57BL/6 mice. Initial experiments assessing the combination of cisplatin with prolonged AZD6738 treatment revealed no significant difference in tumor volume, although a notable increase in CD8⁺ T cell infiltration was observed following ATR inhibition. Subsequently, the therapeutic impact of integrating AZD6738 with cisplatin and the immune checkpoint inhibitor αPD1 was evaluated. Using a short-course ATRi regimen alongside chemotherapy, followed by one or two cycles of αPD1 immunotherapy, we found that the triple combination conferred the greatest tumor suppression. Tumor growth arrest was observed by day 11 but resumed following treatment cessation or upon repeated αPD1 dosing. These findings suggest that DNA damage induced by combined chemotherapy and ATR inhibition may transiently enhance neoantigen exposure, promote immunogenic cell death, and activate the cGAS/STING pathway -collectively fostering a potent yet time-limited anti-tumor immune response. Tumor progression after treatment withdrawal may reflect declining immunostimulatory signaling or suboptimal T cell priming/exhaustion during αPD1 exposure.Notably, extended αPD1 therapy increased total CD3⁺ T cell infiltration without a concomitant rise in CD4⁺ or CD8⁺ subsets, suggesting enrichment of double-negative (DN) T cells—an unconventional population associated with immune modulation. Indeed, DN T cells constituted a high proportion of tumor-infiltrating T cells (~30–80% of CD3⁺), but only a minor subset in spleens (~5–12%). AZD6738 and repeated αPD1 dosing markedly expanded DN T cells within tumors (up to ~60–80%), indicating a tumor-specific enrichment potentially driven by treatment-induced immune modulation. These observations raise the possibility that DN T cells play an active role in shaping the immune response within the tumor microenvironment under specific therapeutic conditions.In conclusion, while immune checkpoint blockade facilitates tumor infiltration by T cells, optimizing the immunostimulatory microenvironment is crucial to sustaining effective anti-tumor responses. Our findings provide insights into DDR-immune system interactions and support the rationale for combinatorial regimens involving ATR inhibitors, chemotherapy, and ICIs—tailored to tumor-specific molecular profiles and treatment kinetics—to maximize clinical benefit.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2025

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Mavroeidi, Dimitra
  • Μαυροειδή, Δήμητρα

Subjects

dc:subject × 20

Rights

Language dc:language
eng

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/60316

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Mavroeidi, Dimitra; Μαυροειδή, Δήμητρα. The interplay of DNA damage response and immune system network in lung cancer therapy. National and Kapodistrian University of Athens, 2025. http://hdl.handle.net/10442/hedi/60316